Announcing the launch of Breakthroughs Today, Cures Tomorrow, our 20th anniversary campaign!
Neuroendocrine cancer patients traveling for pleasure, business, or cancer treatment, may need to consider a few extra details to ensure travel goes smoothly. These travel
NETRF-funded researchers identified a cancer cell type that is associated with non-functional pancreatic neuroendocrine tumor (pNET) recurrence. Alpha-like pNET cell expression of the protein ARX can guide prognosis.
NETRF’s Board of Scientific Advisors and external reviewers will begin reading and ranking the 2019 requests for research funding. Wide Range of Requests for NET
Neuroendocrine cancer community faces loss. Carol Branaman, vice chair and former chair of NETRF, passes from neuroendocrine cancer.
From a place of discouragement after being diagnosed with a NET in June 2018, Susan Garrett of Roxboro, NC, saw a news story on WRAL
Latest in NET Cancer Research Neuroendocrine Tumor Research Foundation (NETRF) held its 11th Annual Research Symposium on May 2-3, 2019, in Cambridge, MA. More than
NETRF & Broad Institute Work to Fill Research Void The lack of publicly available, reliable NET cell lines is a barrier in neuroendocrine tumor research,
Increasing Precision in Cancer Cell Death to Prevent Metastasis In housework and lawn work, it is important to have the right tool for the job.
NETRF given the highest ranking for financial responsibility and transparency by leading nonprofit rating program, GoldStar.
NETRF is so pleased to report that we received several gifts honoring many NET doctors around the country on March 30th, National Doctor’s Day! Thank